1Moak JL. Thrombotic microangiopathie[J]. N Engl J Med, 2002, 347:589-600.
2Tun NM, Villani GM. Efficacy of rituxim~) in acute refractolT or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis[ J]. J Thromb Thrombolysis, 2012, 34:347-359.
3George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome[ J]. Blood, 2000, 96 : 1223- 1229.
4Shumak KH, Rock GA, Nair RC. Late relapses in patients successfully treated for thrombotic thromboeytopenic purpura. Canadian Apheresis Group [J]. Ann Intern Med, 1995, 122: 569-572.
5Caramazza D, Quintini G, Abbene I, et al. Relapsing or refractory idiopathic thrombotic thromboeytopenic purpura-hemolytie uremic syndrome : the role of rituximab [ J ]. Transfusion, 2010, 50 : 2753- 2760.
6Kappers-Klunne MC, Wijemmns P, Fijnheer R, et al. Splenectomy for the treatment of thrombotic thrombocytopenic purpura[ J]. Br J Haematol, 2005, 130:768-776.
7Kivity S, Agmon-Levin N. Rituxirnab for Thrombotic Thrombocytopenic Purpura[J]. Isr Med Assoc J, 2011, 13(7) : 436-437.
8Caramazza D, Quintini G, Abbene I, et al. Relapsing or refractory idiopathic thrombotic thrombocytopenic pmpura-hemolytie uremic syndrome : the role of rituximab [ J ]. Transfusion, 2010, 50:2753- 2760.
